Literature DB >> 23855309

Reversal of hepatitis B virus-induced systemic immune tolerance by intrinsic innate immune stimulation.

Qiuju Han1, Peixiang Lan, Jian Zhang, Cai Zhang, Zhigang Tian.   

Abstract

Systemic immune tolerance induced by chronic hepatitis B virus (HBV) infection is a significant question, but the mechanism of which remains unclear. In this mini-review, we summarize the impaired innate and adaptive immune responses involved in immune tolerance in chronic HBV infection. Furthermore, we delineate a novel dual functional small RNA to inhibit HBV replication and stimulate innate immunity against HBV, which proposed a promising immunotherapeutic intervention to interrupt HBV-induced immunotolerance. A mouse model of HBV persistence was established and used to observe the immune tolerant to HBV vaccination, the cell-intrinsic immune tolerance of which might be reversed by chemically synthesized dual functional small RNA (3p-hepatitis B Virus X gene [HBx]-small interfering RNA) in vitro experiments and by biologically constructed dual functional vector (single-stranded RNA-HBx- short hairpin RNA) in vivo experiment using HBV-carrier mice.
© 2013 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  HBV; immune tolerance; intrinsic immunity

Mesh:

Substances:

Year:  2013        PMID: 23855309     DOI: 10.1111/jgh.12034

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  8 in total

1.  Analysis of immunological mechanisms exerted by HBsAg-HBIG therapeutic vaccine combined with Adefovir in chronic hepatitis B patients.

Authors:  Chenliang Zhou; Chaofan Li; Guo-Zhong Gong; Shuang Wang; Ji-Ming Zhang; Dao-Zhen Xu; Li-Min Guo; Hong Ren; Min Xu; Qing Xie; Chen Pan; Jie Xu; Zhongyu Hu; Shuang Geng; Xian Zhou; Xianzheng Wang; Xiaoyu Zhou; Haili Mi; Gan Zhao; Wencong Yu; Yu-Mei Wen; Lihua Huang; Xuan-Yi Wang; Bin Wang
Journal:  Hum Vaccin Immunother       Date:  2017-06-30       Impact factor: 3.452

2.  Vaccines targeting preS1 domain overcome immune tolerance in hepatitis B virus carrier mice.

Authors:  Yingjie Bian; Zheng Zhang; Zhichen Sun; Juanjuan Zhao; Danming Zhu; Yang Wang; Sherry Fu; Jingya Guo; Longchao Liu; Lishan Su; Fu-Sheng Wang; Yang-Xin Fu; Hua Peng
Journal:  Hepatology       Date:  2017-08-26       Impact factor: 17.425

3.  Inflammatory bowel disease: Traditional knowledge holds the seeds for the future.

Authors:  Giovanni C Actis; Rinaldo Pellicano; Floriano Rosina
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-05-06

4.  Overcoming HBV immune tolerance to eliminate HBsAg-positive hepatocytes via pre-administration of GM-CSF as a novel adjuvant for a hepatitis B vaccine in HBV transgenic mice.

Authors:  Xianzheng Wang; Aihua Dong; Jingjing Xiao; Xingjun Zhou; Haili Mi; Hanqian Xu; Jiming Zhang; Bin Wang
Journal:  Cell Mol Immunol       Date:  2015-07-13       Impact factor: 11.530

Review 5.  Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy.

Authors:  Cheng Sun; Hao-yu Sun; Wei-hua Xiao; Cai Zhang; Zhi-gang Tian
Journal:  Acta Pharmacol Sin       Date:  2015-06-15       Impact factor: 6.150

Review 6.  Combinational immune-cell therapy of natural killer cells and sorafenib for advanced hepatocellular carcinoma: a review.

Authors:  Faezeh Hosseinzadeh; Javad Verdi; Jafar Ai; Saieh Hajighasemlou; Iman Seyhoun; Frzad Parvizpour; Fatemeh Hosseinzadeh; Abolfazl Iranikhah; Sadegh Shirian
Journal:  Cancer Cell Int       Date:  2018-09-10       Impact factor: 5.722

7.  Genome-Wide CRISPR Screen Identifies Host Factors Required by Toxoplasma gondii Infection.

Authors:  Shui-Zhen Wu; Hai-Xia Wei; Dan Jiang; Sheng-Min Li; Wei-Hao Zou; Hong-Juan Peng
Journal:  Front Cell Infect Microbiol       Date:  2020-01-22       Impact factor: 5.293

8.  Quantitative HBsAg versus HBV DNA in Predicting Significant Hepatitis Activity of HBeAg-Positive Chronic HBV Infection.

Authors:  Zhanqing Zhang; Wei Lu; Dong Zeng; Dan Huang; Weijia Lin; Li Yan; Yanling Feng
Journal:  J Clin Med       Date:  2021-11-29       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.